Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

Somatic SETBP1 mutations in myeloid malignancies

(2013) Hideki Makishima et al.   NATURE GENETICS

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS

(2012) Aaron T. Gerds et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

(2012) F. Thol et al.   BLOOD

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia

(2012) Harriet Holme et al.   BRITISH JOURNAL OF HAEMATOLOGY

MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation

(2012) M. Wermke et al.   CLINICAL CANCER RESEARCH

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

(2012) N. Gattermann et al.   HAEMATOLOGICA

Molecular pathogenesis and clinical management of Fanconi anemia

(2012) Younghoon Kee et al.   JOURNAL OF CLINICAL INVESTIGATION

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

(2012) Alan F. List et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

(2012) Gandhi Damaj et al.   JOURNAL OF CLINICAL ONCOLOGY

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

(2012) Julie Schanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Myelodysplastic Syndrome and Benzene Exposure Among Petroleum Workers: An International Pooled Analysis

(2012) A. R. Schnatter et al.   JNCI-Journal of the National Cancer Institute

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

(2012) T M Westers et al.   LEUKEMIA

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

(2012) Claudio Anasetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer

(2012) Matti Aapro et al.   Therapeutic Advances in Medical Oncology

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

(2011) L. Malcovati et al.   BLOOD

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies

(2011) R. V. Tiu et al.   BLOOD

Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes

(2011) Noémi B. A. Roy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study

(2011) Marianne Haag-Weber et al.   CLINICAL NEPHROLOGY

Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

(2011) A. Villegas et al.   CURRENT MEDICAL RESEARCH AND OPINION

Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions

(2011) Herman Nilsson-Ehle et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange

(2011) Norbert Gattermann et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors

(2011) S. Parmentier et al.   HAEMATOLOGICA

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

(2011) L. Malcovati et al.   HAEMATOLOGICA

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes

(2011) F. Thol et al.   HAEMATOLOGICA

Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome

(2011) Jaroslav Cermak et al.   HEMOGLOBIN

Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model

(2011) Kiran Naqvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes

(2011) Felicitas Thol et al.   JOURNAL OF CLINICAL ONCOLOGY

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

(2011) Julie Schanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

(2011) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance

(2011) V Grossmann et al.   LEUKEMIA

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

(2011) M J Walter et al.   LEUKEMIA

Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry

(2011) Judith Neukirchen et al.   LEUKEMIA RESEARCH

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

(2011) Timothy A Graubert et al.   NATURE GENETICS

Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia

(2011) Christopher N Hahn et al.   NATURE GENETICS

SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts

(2011) E. Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation

(2010) Philippe Armand et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

(2010) H. M. Kantarjian et al.   BLOOD

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

(2010) R. Itzykson et al.   BLOOD

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

(2010) Mikkael A. Sekeres et al.   CANCER

Incidence of myelodysplastic syndromes in a Swedish population

(2010) Anders Rådlund et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Treatment of myelodysplastic syndromes with human granulocytic-macrophage colony stimulating factor (GM-CSF) or GM-CSF combined with low-dose cytosine arabinoside

(2010) T. Economopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Treatment of myelodysplastic syndromes with retinoic acid and 1α-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study

(2010) Eva Hellström et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The European LeukemiaNet: achievements and perspectives

(2010) R. Hehlmann et al.   HAEMATOLOGICA

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

(2010) T. de Witte et al.   HAEMATOLOGICA

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome

(2010) M. G. Della Porta et al.   HAEMATOLOGICA

Prognostic Classification and Risk Assessment in Myelodysplastic Syndromes

(2010) Mario Cazzola et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries

(2010) Stuart L. Goldberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care—SAKK 33/99

(2010) Jakob R. Passweg et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma

(2010) Corrado Tarella et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML

(2010) F Dicker et al.   LEUKEMIA

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia

(2010) J Boultwood et al.   LEUKEMIA

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

(2010) O Kosmider et al.   LEUKEMIA

Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life

(2010) Esther N. Oliva et al.   LEUKEMIA & LYMPHOMA

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

(2010) Norbert Gattermann et al.   LEUKEMIA RESEARCH

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

(2010) Gorica Nikoloski et al.   NATURE GENETICS

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review

(2009) Deborah J. Pinchon et al.   AMERICAN JOURNAL OF HEMATOLOGY

Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group

(2009) W. R. Sperr et al.   ANNALS OF ONCOLOGY

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

(2009) T. M. Westers et al.   BLOOD

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

(2009) P. L. Greenberg et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia

(2009) Valentina Tzekova et al.   CURRENT MEDICAL RESEARCH AND OPINION

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

(2009) E. Zipperer et al.   HAEMATOLOGICA

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

(2009) M. D. Cappellini et al.   HAEMATOLOGICA

Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach

(2009) J. M. Bennett et al.   HAEMATOLOGICA

Morphological evaluation of monocytes and their precursors

(2009) J. E. Goasguen et al.   HAEMATOLOGICA

Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study

(2009) E. P. Alessandrino et al.   HAEMATOLOGICA

Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome

(2009) M. G. D. Porta et al.   HAEMATOLOGICA

Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study

(2009) K. Ogata et al.   HAEMATOLOGICA

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

(2009) A. A. van de Loosdrecht et al.   HAEMATOLOGICA

Hypocellular Myelodysplasia

(2009) Elaine M. Sloand   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies

(2009) Hideki Makishima et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

(2009) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

(2009) ZiYi Lim et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation

(2009) Z.Y. Lim et al.   LEUKEMIA RESEARCH

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telomere Diseases

(2009) Rodrigo T. Calado et al.   NEW ENGLAND JOURNAL OF MEDICINE

HX575, Recombinant Human Epoetin Alfa, for the Treatment of Chemotherapy-Associated Symptomatic Anaemia in Patients with Solid Tumours

(2009) Karin Weigang-Köhler et al.   Oncology Research and Treatment

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes

(2008) Jelena M. Kao et al.   AMERICAN JOURNAL OF HEMATOLOGY

A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes

(2008) Jason Gotlib et al.   AMERICAN JOURNAL OF HEMATOLOGY

Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS)

(2008) Uwe Platzbecker et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Whole genome scanning as a cytogenetic tool in hematologic malignancies

(2008) J. P. Maciejewski et al.   BLOOD

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome

(2008) B. L. Scott et al.   BLOOD

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

(2008) D. E. Rollison et al.   BLOOD

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

(2008) Janice Gabrilove et al.   BRITISH JOURNAL OF HAEMATOLOGY

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

(2008) Hagop Kantarjian et al.   CANCER

Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias

(2008) A. A. Di Tucci et al.   HAEMATOLOGICA

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

(2008) G. J. Mufti et al.   HAEMATOLOGICA

Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy

(2008) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome

(2008) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes

(2008) Matteo Giovanni Della Porta et al.   JOURNAL OF CLINICAL ONCOLOGY

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

(2008) Benjamin L Ebert et al.   PLOS MEDICINE

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

(2007) S. Park et al.   BLOOD